TY  - JOUR
A1  - Brauer, R
A1  - Wong, ICK
A1  - Man, KKC
A1  - Pratt, NL
A1  - Park, RW
A1  - Cho, S-Y
A1  - Li, Y-CJ
A1  - Iqbal, U
A1  - Nguyen, P-AA
A1  - Schuemie, M
IS  - 1
VL  - 10
ID  - discovery10089674
AV  - public
TI  - Application of a Common Data Model (CDM) to rank the paediatric user and prescription prevalence of 15 different drug classes in South Korea, Hong Kong, Taiwan, Japan and Australia: an observational, descriptive study
N1  - This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
JF  - BMJ Open
Y1  - 2020/01/13/
UR  - https://doi.org/10.1136/bmjopen-2019-032426
N2  - Objective: To measure the paediatric user and prescription prevalence in inpatient and ambulatory settings in South Korea, Hong Kong, Taiwan, Japan and Australia by age and gender. A further objective was to list the most commonly used drugs per drug class, per country.

Design and setting: Hospital inpatient and insurance paediatric healthcare data from the following databases were used to conduct this descriptive drug utilisation study: (i) the South Korean Ajou University School of Medicine database; (ii) the Hong Kong Clinical Data Analysis and Reporting System; (iii) the Japan Medical Data Center; (iv) Taiwan?s National Health Insurance Research Database and (v) the Australian Pharmaceutical Benefits Scheme. Country-specific data were transformed into the Observational Medical Outcomes Partnership Common Data Model.

Patients: Children (?18 years) with at least 1 day of observation in any of the respective databases from January 2009 until December 2013 were included.

Main outcome measures: For each drug class, we assessed the per-protocol overall user and prescription prevalence rates (per 1000 persons) per country and setting.

Results: Our study population comprised 1 574 524 children (52.9% male). The highest proportion of dispensings was recorded in the youngest age category (<2 years) for inpatients (45.1%) with a relatively high user prevalence of analgesics and antibiotics. Adrenergics, antihistamines, mucolytics and corticosteroids were used in 10%?15% of patients. For ambulatory patients, the highest proportion of dispensings was recorded in the middle age category (2?11 years, 67.1%) with antibiotics the most dispensed drug overall.

Conclusions: Country-specific paediatric drug utilisation patterns were described, ranked and compared between four East Asian countries and Australia. The widespread use of mucolytics in East Asia warrants further investigation.
PB  - BMJ
ER  -